Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications

References

• World Health Organization. Global report on diabetes. Geneva: World Health Organization; 2016. p. 86.
   Google Scholar
• International Diabetes Federation. IDF diabetes atlas. 7th ed. Brussels: International Diabetes Federation; 2015.
   Google Scholar
• Kassahun T, Eshetie T, Gesesew H. Factors associated with glycemic control among adult patients with type 2 diabetes mellitus: a cross-sectional survey in Ethiopia. BMC Res Notes. 2016 Dec 9;9(1):78.
   PubMedGoogle Scholar
• Brasil. Relação Nacional de Medicamentos Essenciais: RENAME 2014. 9th ed. Brasília: Ministério da Saúde; 2015. p. 228.
   Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Bmj. 1998 Sep 12;317(7160):703–713.
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol. 2006 Apr 1;17(4_suppl_2):S90–7.
   Google Scholar
• Collins R, Armitage J, Parish S, et al., Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003 Jun; 361(9374):2005–2016.
   PubMed Web of Science ®Google Scholar
• Godman B, Malmström RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015 Jan 2;8(1):77–94.
   PubMed Web of Science ®Google Scholar
• Bolen S, Tseng E, Hutfless S, et al. Diabetes medications for adults with type 2 diabetes: an update [internet]. Rockville (MD): AHRQ Comparative Effectiveness Reviews; 2016.
   Google Scholar
• Hippisley-Cox J, Coupland C. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. BMJ. 2016 Jul 12;i3477.
   Google Scholar
• Wise J. Metformin is backed as first line therapy for type 2 diabetes. BMJ. 2016 Apr 19;353:i2236.
   Google Scholar
• Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes. Ann Intern Med. 2016 Jun 7;164(11):740.
   PubMed Web of Science ®Google Scholar
• Shih C-J, Chen H-T, Kuo S-C, et al. Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in elderly patients with type 2 diabetes: a nationwide study. J Am Med Dir Assoc. 2016 Jan;17(1):59–64.
   PubMed Web of Science ®Google Scholar
• Fisman EZ, Tenenbaum A. Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovasc Diabetol. 2015 Dec 29;14(1):129.
   PubMed Web of Science ®Google Scholar
• McInnes G, Evans M, Del Prato S, et al. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. Diabetes, Obes Metab. 2015 Nov;17(11):1085–1092.
   PubMed Web of Science ®Google Scholar
• Karagiannis T, Bekiari E, Boura P, et al. Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf. 2016 Apr 1;7(2):36–38.
   PubMedGoogle Scholar
• Thompson PL, Davis TME. Cardiovascular effects of glucose-lowering therapies for type 2 diabetes: new drugs in perspective. Clin Ther. 2016 Nov 15. pii: S0149-2918(16)30793-7.
   Google Scholar
• Barkas F, Elisaf M, Tsimihodimos V, et al. Dipeptidyl peptidase-4 inhibitors and protection against stroke: a systematic review and meta-analysis. Diabetes Metab. 2017; 43(1):1–8.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Benedict Á, Muszbek N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract. 2007 Nov 5;62(1):76–87.
   PubMed Web of Science ®Google Scholar
• Awodele O, Osuolale J. Medication adherence in type 2 diabetes patients: study of patients in Alimosho General Hospital, Igando, Lagos, Nigeria. Afr Health Sci. 2015 May 28;15(2):513.
   PubMed Web of Science ®Google Scholar
• García-Pérez L-E, Álvarez M, Dilla T, et al. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013 Dec 30;4(2):175–194.
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Navarro-Artieda R. Healthcare costs of the combination of metformin/dipeptidyl peptidase-4 inhibitors compared with metformin/other oral antidiabetes agents in patients with type 2 diabetes and metabolic syndrome. Diabetes Technol Ther. 2014 Nov;16(11):722–727.
   PubMed Web of Science ®Google Scholar
• Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-iv inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005 Aug;90(8):4888–4894.
   PubMed Web of Science ®Google Scholar
• Bekiari E, Rizava C, Athanasiadou E, et al. Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine. 2016 Jun 29;52(3):458–480.
   PubMed Web of Science ®Google Scholar
• De Souza ALC, De A Acurcio F, Júnior AAG, et al. Insulin glargine in a Brazilian State: should the government disinvest? An assessment based on a systematic review. Appl Health Econ Health Policy. 2014 Feb 3;12(1):19–32.
   PubMedGoogle Scholar
• Brasil. Banco de Preços em Saúde – BPS. Brasília: Ministério da Saúde; 2015.
   Google Scholar
• Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322–338.
   PubMed Web of Science ®Google Scholar
• Schweizer A, Couturier A, Foley JE, et al. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabet Med. 2007 Sep;24(9):955–961.
   PubMed Web of Science ®Google Scholar
• Bolli G, Dotta F, Colin L, et al. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes, Obes Metab. 2009 Jun;11(6):589–595.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obes Metab. 2009 Feb;11(2):157–166.
   PubMed Web of Science ®Google Scholar
• Filozof C, Gautier J-F. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med. 2010 Mar;27(3):318–326.
   PubMed Web of Science ®Google Scholar
• Mathieu C, Barnett AH, Brath H, et al. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract. 2013 Oct;67(10):947–956.
   PubMed Web of Science ®Google Scholar
• Montilla S, Marchesini G, Sammarco A, et al. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutr Metab Cardiovasc Dis. 2014 Dec;24(12):1346–1353.
   PubMed Web of Science ®Google Scholar
• Brazil. SIHSUS - DATASUS [Internet]. SIHSUS - Sistema de Informações Hospitalares do SUS. 2016 [cited 2016 Jul 1]. Available from: http://datasus.saude.gov.br/sistemas-e-aplicativos/hospitalares/sihsus
   Google Scholar
• Brazil. SIA - DATASUS [Internet]. SIA - Sistema de Informações Ambulatoriais do SUS. 2016 [cited 2016 Jul 1]. Available from: http://datasus.saude.gov.br/sistemas-e-aplicativos/ambulatoriais/sia
   Google Scholar
• Belo Horizonte. Transparência e acesso à informação – Remuneração – Servidores ativos [internet]. 2016 [cited 2016 Jul 1]. Available from: http://portalpbh.pbh.gov.br/pbh/ecp/comunidade.do?evento=portlet&pIdPlc=ecpTaxonomiaMenuPortal&app=acessoinformacao&tax=41984&lang=pt_BR&pg=10125&taxp=0&
   Google Scholar
• Berger ML, Bingefors K, Hedblom EC, et al. Health care cost, quality and outcomes: ISPOR book of terms. 1st ed. Lawrenceville, NJ: ISPOR; 2003. p. 264.
   Google Scholar
• The World Bank. PPP conversion factor, GDP (LCU per international $) [Internet]. 2016 [cited 2016 Jul 15]. Available from: http://data.worldbank.org/indicator/PA.NUS.PPP
   Google Scholar
• IBGE. IBGE |brasil em síntese |contas nacionais |PIB - per capita [Internet]. PIB - Per capita - Brasil - 2009/2015. 2016 [cited 2016 Jul 1]. Available from: http://brasilemsintese.ibge.gov.br/contas-nacionais/pib-per-capita
   Google Scholar
• Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006. p. 237.
   Google Scholar
• Godman B, Gustafsson LL. A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing. Appl Health Econ Health Policy. 2013 Feb 16;11(1):79–82.
   PubMedGoogle Scholar
• Paris V, Belloni A. Value in pharmaceutical pricing. OECD Heal Work Pap. Paris. 2013;63:74.
   Google Scholar
• Godman B, Campbell S, Suh HS, et al. Ongoing measures to enhance prescribing efficiency across Europe: implications for other countries. J Heal Tech Assess. 2013;1:27–42.
   Google Scholar
• Ford JA, Waugh N, Sharma P, et al. NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium. BMJ Open. 2012 Jan 30;2(1):e000671.
   Google Scholar
• Svensson M, Nilsson FOL, Arnberg K. Reimbursement decisions for pharmaceuticals in Sweden: the impact of disease severity and cost effectiveness. Pharmacoeconomics. 2015 Nov 21;33(11):1229–1236.
   PubMed Web of Science ®Google Scholar
• Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. In: Richter B, editor. Cochrane database of systematic reviews. Chichester, UK: John Wiley & Sons, Ltd; 2008. p. CD006739.
   Google Scholar
• Waugh N, Cummins E, Royle P, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess (Rockv). 2010 Jul;14(36):1–248.
   Web of Science ®Google Scholar
• Viriato D, Calado F, Gruenberger J-B, et al. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective. J Med Econ. 2014 Jul 23;17(7):499–507.
   PubMedGoogle Scholar
• Hayes AJ, Leal J, Gray AM, et al. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013 Sep 22;56(9):1925–1933.
   PubMed Web of Science ®Google Scholar
• Nita ME, Eliaschewitz FG, Ribeiro E, et al. Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system. Rev Assoc Med Bras. 2012 May;58(3):294–301.
   PubMed Web of Science ®Google Scholar
• Geng J, Yu H, Mao Y, et al. Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Pharmacoeconomics. 2015 Jun 4;33(6):581–597.
   PubMed Web of Science ®Google Scholar
• Baptista A, Teixeira I, Romano S, et al. The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies. Eur J Heal Econ. 2016 Oct 17. Epub ahead of print
   PubMedGoogle Scholar
• Charokopou M, McEwan P, Lister S, et al. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to metformin in the treatment of type 2 diabetes mellitus from a UK Healthcare System Perspective. BMC Health Serv Res. 2015 Jun 5;15(1):496.
   PubMed Web of Science ®Google Scholar
• Towards better patient care: drugs to avoid in 2016. Prescrire Int. 2016 Apr;25(170):105–111.
   PubMedGoogle Scholar
• Ahuja V, Chou C-H. Novel therapeutics for diabetes: uptake, usage trends, and comparative effectiveness. Curr Diab Rep. 2016 Jun 13;16(6):47.
   PubMed Web of Science ®Google Scholar